Effect of plasma exchange on the steady-state kinetics of digoxin and digitoxin.

Abstract:

:The pharmacokinetic effect of extracorporeal elimination can be evaluated from the extracorporeal elimination rate constant, from the amount of drug removed, and from extracorporeal clearance. To compare the validity of these approaches in clinical practice, the effect of multiple plasma exchanges on the steady-state kinetics of digoxin (5 patients) and digitoxin (9) was investigated. For digoxin, an unchanged elimination half-life (28 hours) and only slight increase in the total body clearance was found (from 203 to 204 ml/min). There was a more pronounced effect on the kinetics of digitoxin, where the elimination half-life decreased from 4.3 to 3.6 days, and the total body clearance increased from 4.4 to 4.7 ml/min. For digoxin there was no statistically significant difference between observed and predicted steady-state trough plasma concentrations. For digitoxin, the observed trough plasma concentrations at steady-state correlated well (p less than 0.05) with the predicted concentrations calculated from the amount removed or from extracorporeal clearance. The magnitude of the kinetic effect of plasma exchange is overestimated using the extracorporeal elimination rate constant; but the effect of extracorporeal elimination can be adequately evaluated from the amount of drug removed and from extracorporeal clearance. These later approaches can be considered model-independent. Thus, the influence of multiple plasma exchanges on the steady-state kinetics of digoxin and digitoxin will be limited and dosage adjustment is not required, if these drugs are given after - not before - the procedure and hypoalbuminaemia is corrected.

journal_name

Clin Pharmacokinet

authors

Keller F,Kreutz G,Vöhringer HF,Offermann G,Distler A

doi

10.2165/00003088-198510060-00004

subject

Has Abstract

pub_date

1985-11-01 00:00:00

pages

514-23

issue

6

eissn

0312-5963

issn

1179-1926

journal_volume

10

pub_type

杂志文章
  • Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods.

    abstract::The influence of anaesthesia and surgery on the pharmacokinetics of pethidine (meperidine) was studied in 12 patients. Plasma pethidine concentrations in central venous blood collected during anaesthesia and the ensuing postoperative hours were by gas chromatography with electron capture detection. Postoperative analg...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章

    doi:10.2165/00003088-198207020-00004

    authors: Tamsen A,Hartvig P,Fagerlund C,Dahlström B

    更新日期:1982-03-01 00:00:00

  • The pharmacokinetics of zileuton in healthy young and elderly volunteers.

    abstract::The effects of age and gender on the single and multiple dose pharmacokinetics of zileuton have been examined in a phase I nonblinded study. A total of 27 healthy volunteers were evaluable, 9 in the young group (age range 20 to 40 years; 5 males and 4 females) and 18 in the elderly group (range 65 to 81 years; 9 males...

    journal_title:Clinical pharmacokinetics

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003088-199500292-00007

    authors: Braeckman RA,Granneman GR,Locke CS,Machinist JM,Cavannaugh JH,Awni WM

    更新日期:1995-01-01 00:00:00

  • Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

    abstract::Ethnic or racial differences in pharmacokinetics and pharmacodynamics have been attributed to the distinctions in the genetic, physiological and pathological factors between ethnic/racial groups. These pharmacokinetic/pharmacodynamic differences are also known to be influenced by several extrinsic factors such as soci...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-200645100-00001

    authors: Chen ML

    更新日期:2006-01-01 00:00:00

  • Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children.

    abstract:OBJECTIVE:The aims of this study were to (1) determine whether opportunistically collected data can be used to develop physiologically based pharmacokinetic (PBPK) models in pediatric patients; and (2) characterize age-related maturational changes in drug disposition for the renally eliminated and hepatically metaboliz...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/s40262-018-00733-1

    authors: Thompson EJ,Wu H,Maharaj A,Edginton AN,Balevic SJ,Cobbaert M,Cunningham AP,Hornik CP,Cohen-Wolkowiez M

    更新日期:2019-07-01 00:00:00

  • Pharmacokinetics in the elderly.

    abstract::The elderly are generally considered to be different from young people in terms of drug response and this applies particularly to quantitative differences. While altered drug handling is a major potential source of difference in responsiveness to drugs, the relative contribution of pharmacokinetics and pharmacodynamic...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-197601040-00003

    authors: Crooks J,O'Malley K,Stevenson IH

    更新日期:1976-01-01 00:00:00

  • The influence of renal function on plasma concentration, urinary excretion and antihypertensive effect of guanfacine.

    abstract::18 hypertensive patients with a glomerular filtration rate (GFR) between 3.8 and 113ml/min received guanfacine as single intravenous and multiple oral dose treatment. Mean plasma concentrations of guanfacine on the fifth day or oral treatment ranged from 6.5 to 8.6ng/ml in patients with normal renal function (GFR > 90...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章

    doi:10.2165/00003088-198005050-00005

    authors: Kirch W,Köhler H,Braun W,von Gizycki C

    更新日期:1980-09-01 00:00:00

  • Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.

    abstract:BACKGROUND:Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase currently being developed for the management of hyperuricemia in patients with gout. OBJECTIVE:To investigate the pharmacokinetics, pharmacodynamics and safety of febuxostat over a range of oral doses in healthy subjects. METHODS:In a...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00003088-200645080-00005

    authors: Khosravan R,Grabowski BA,Wu JT,Joseph-Ridge N,Vernillet L

    更新日期:2006-01-01 00:00:00

  • Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.

    abstract::Although individualised antihypertensive therapy is widely recommended, prospective methods for optimising treatment are hampered by the paucity of basic information about dose-plasma concentration-response relationships for commonly used drugs. Concentration-effect analysis has been applied to a number of therapeutic...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199426060-00005

    authors: Donnelly R,Elliott HL,Meredith PA

    更新日期:1994-06-01 00:00:00

  • Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

    abstract::Population pharmacokinetic and pharmacodynamic analysis is an important tool to support optimal treatment in clinical oncology. The population approach is suitable to explain variability between patients and to establish relationships between drug exposure and a relevant pharmacodynamic parameter. This can facilitate ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-200847080-00001

    authors: Zandvliet AS,Schellens JH,Beijnen JH,Huitema AD

    更新日期:2008-01-01 00:00:00

  • Clinical pharmacokinetics of the newer intravenous anaesthetic agents.

    abstract::In the last 15 years the role of opioids in anaesthesia management has undergone dramatic change. Initially used as premedicants, or adjuvants to inhalation anaesthetic agents or as analgesics for postoperative pain relief, narcotics have now evolved into primary anaesthetic agents, primarily because of their ability ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-198611010-00002

    authors: Davis PJ,Cook DR

    更新日期:1986-01-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients.

    abstract:OBJECTIVE:A prospective pharmacokinetic study was performed in Caucasian patients from an intensive care unit with respiratory support to evaluate the influence of this circumstance on the pharmacokinetic behaviour of levofloxacin. PATIENTS AND METHODS:A standard dosage regimen of 500 mg/day was administered to nine C...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章

    doi:10.2165/00003088-200544060-00004

    authors: Sánchez Navarro A,Colino Gandarillas CI,Alvarez Lerma F,Menacho YA,Domínguez-Gil A

    更新日期:2005-01-01 00:00:00

  • Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

    abstract::Histamine H2-receptor antagonists are a unique class of compounds. Pharmacologically they are characterised as a family by their ability to inhibit the secretion of gastric acid, and kinetically they are classified as a family by their similarity in absorption, distribution and elimination. All the H2-receptor antagon...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199120030-00004

    authors: Lin JH

    更新日期:1991-03-01 00:00:00

  • Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

    abstract::In the treatment of patients with Parkinson's disease, apomorphine has an established place as a back-up therapy if other antiparkinsonian drugs, such as levodopa and oral dopamine agonists, have not controlled the existing response fluctuations. Apomorphine is a synthetic derivative of morphine, with a totally distin...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199937030-00004

    authors: Neef C,van Laar T

    更新日期:1999-09-01 00:00:00

  • Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

    abstract::In the drug therapy of cardiac emergencies, it is necessary to rapidly achieve therapeutic drug concentrations and adjust drug dose as the patient's clinical status changes. Cardiac dysfunction is often present and may alter drug pharmacokinetics. Circulatory failure causes sympathetically mediated vasoconstriction in...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-198409040-00001

    authors: Pentel P,Benowitz N

    更新日期:1984-07-01 00:00:00

  • Salivary antipyrine half-life during injectable progestagen contraception.

    abstract::Antipyrine pharmacokinetics were studied in 6 healthy women before and 2, 8 and 12 weeks after administering the injectable progestagen (progestin), norethisterone (norethindrone) enanthate 200mg intramuscularly. Additionally, antipyrine kinetics in 5 women who had previously used the injectable contraceptive for 8 to...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章

    doi:10.2165/00003088-198611020-00007

    authors: Joshi JV,Gupta KC,Hazari KT,Gokral J,Pohujani S,Satoskar R

    更新日期:1986-03-01 00:00:00

  • Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

    abstract::Despite contributing significantly to the burden of global disease, the translation of new treatment strategies for diseases of the central nervous system (CNS) from animals to humans remains challenging, with a high attrition rate in the development of CNS drugs. The failure of clinical trials for CNS therapies can b...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.1007/s40262-018-0632-y

    authors: Srinivas N,Maffuid K,Kashuba ADM

    更新日期:2018-09-01 00:00:00

  • Cyclosporin clinical pharmacokinetics.

    abstract::Cyclosporin is a powerful immunosuppressive drug used in transplantation medicine and to treat autoimmune diseases. It is a lipophilic molecule, with its bioavailability dependent on food, bile and other interacting factors. Cyclosporin is extensively metabolised in the liver by the cytochrome P450 3A system, which is...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199324060-00004

    authors: Fahr A

    更新日期:1993-06-01 00:00:00

  • Author Correction: Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?

    abstract::In the original publication, Page 3, Sect. 4.3, the first sentence was incorrectly published. ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40262-018-0633-x

    authors: Martin JH,Schneider J,Lucas CJ,Galettis P

    更新日期:2018-05-01 00:00:00

  • Pharmacokinetic drug interactions of commonly used anticancer drugs.

    abstract::With the use of combination chemotherapy as well as a wide range of symptomatic therapies (e.g. analgesics and antiemetics) for the treatment of patients with cancer, the field of oncology practises polypharmacy to an extreme degree. The risk for a drug interaction under these conditions is high, and the pharmacologic...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-198611030-00004

    authors: Balis FM

    更新日期:1986-05-01 00:00:00

  • The efficiency concept in pharmacodynamics.

    abstract::The classic approach to describe the pharmacological response to a drug is to analyse its concentration-effect relationship, using a variety of possible models such as maximum effect (Emax) models or sigmoid Emax models. The aim of this review is to discuss an alternative way of describing the pharmacological effect i...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199936050-00005

    authors: Alván G,Paintaud G,Wakelkamp M

    更新日期:1999-05-01 00:00:00

  • Clinical pharmacokinetics of contraceptive steroids. An update.

    abstract::The present article should be read in conjunction with the original review published in the Journal in 1983. There is no new information of major significance about the pharmacokinetics of levonorgestrel, norethisterone (norethindrone) or ethinylestradiol, although it has been shown that the concentrations of these ho...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199120010-00002

    authors: Shenfield GM,Griffin JM

    更新日期:1991-01-01 00:00:00

  • Formation of active metabolites of psychotropic drugs. An updated review of their significance.

    abstract::Most of the currently available psychotropic drugs form 1 or more active metabolites during in vivo biotransformation in humans and/or animals. In some cases these metabolites are rapidly conjugated and excreted, but in others they attain blood and/or brain concentrations within the same range as, or even higher than,...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199018060-00002

    authors: Caccia S,Garattini S

    更新日期:1990-06-01 00:00:00

  • Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

    abstract::The effects of diabetes mellitus on the pharmacokinetics and pharmacodynamics of drugs have been well described in experimental animal models; however, only minimal data exist for humans and the current knowledge regarding the effects of diabetes on these properties remains unclear. Nevertheless, it has been observed ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/11631900-000000000-00000

    authors: Dostalek M,Akhlaghi F,Puzanovova M

    更新日期:2012-08-01 00:00:00

  • Pharmacokinetics of anticancer drugs in children.

    abstract::Interpatient pharmacokinetic variability normally observed in adults is often of even greater magnitude in paediatric patients because of age-related maturation of physiological processes responsible for drug disposition. Several antineoplastic agents have shown age-related changes, including alterations in volume of ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-198712030-00002

    authors: Crom WR,Glynn-Barnhart AM,Rodman JH,Teresi ME,Kavanagh RE,Christensen ML,Relling MV,Evans WE

    更新日期:1987-03-01 00:00:00

  • Drug disposition in cystic fibrosis.

    abstract::There are many pathological changes in patients with cystic fibrosis (CF) which can lead to alterations in drug disposition. Although, in patients with CF, the extent of drug absorption varies widely and the rate of absorption is slower, bioavailability is not altered. Plasma protein binding for the majority of drugs ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199835040-00004

    authors: Rey E,Tréluyer JM,Pons G

    更新日期:1998-10-01 00:00:00

  • Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.

    abstract:OBJECTIVE:To determine the multiple dose pharmacokinetics of a new extended release (ER) capsule formulation of tolterodine, compared with the existing immediate release (IR) tablet, in healthy volunteers. DESIGN:Nonblind, randomised, 2-way crossover trial. PARTICIPANTS:19 healthy volunteers (7 females, 12 males), me...

    journal_title:Clinical pharmacokinetics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003088-200140030-00006

    authors: Olsson B,Szamosi J

    更新日期:2001-01-01 00:00:00

  • Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.

    abstract::Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of adenocarcinoma tumour histology. Nintedanib competitively binds to the kinase domains of vascular endothelial growth factor (VEGF), platelet-de...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.1007/s40262-019-00766-0

    authors: Wind S,Schmid U,Freiwald M,Marzin K,Lotz R,Ebner T,Stopfer P,Dallinger C

    更新日期:2019-09-01 00:00:00

  • Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

    abstract::The combination of artemether and lumefantrine (benflumetol) is a new and very well tolerated oral antimalarial drug effective even against multidrug-resistant falciparum malaria. The artemether component is absorbed rapidly and biotransformed to dihydroartemisinin, and both are eliminated with terminal half-lives of ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-199937020-00002

    authors: White NJ,van Vugt M,Ezzet F

    更新日期:1999-08-01 00:00:00

  • Population Pharmacokinetics of Necitumumab in Cancer Patients.

    abstract::Necitumumab is a second-generation, recombinant, human immunoglobulin G1, epidermal growth factor (EGFR) receptor antibody that specifically blocks the ligand binding site of EGFR. Necitumumab potentially acts by blocking ligand epidermal growth factor (EGF) binding-mediated activation of the EGFR signaling pathway, i...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/s40262-016-0452-x

    authors: Long A,Chigutsa E,Wallin J

    更新日期:2017-05-01 00:00:00

  • Pharmacokinetics of antibiotics in pregnancy and labour.

    abstract::Few of the articles published on antibiotics and pregnancy are concerned with pharmacokinetics. It is particularly difficult to evaluate possible alterations in pharmacokinetic parameters that may be due to pregnancy. Most data available have been obtained in connection with abortion or delivery. Such data may not be ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2165/00003088-197904040-00003

    authors: Philipson A

    更新日期:1979-07-01 00:00:00